Current Report Filing (8-k)
20 August 2022 - 07:28AM
Edgar (US Regulatory)
0000012239 false 0000012239 2022-08-09
2022-08-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 9, 2022
|
AIKIDO
PHARMA INC. |
|
(Exact name of registrant as
specified in its charter) |
| |
|
Delaware |
000-05576 |
52-0849320 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
|
One Rockefeller Plaza,
11th Floor,
New York,
NY |
10020 |
|
(Address of principal executive
offices) |
(Zip Code) |
|
|
|
Registrant’s telephone number, including area code: (703)
993-9325
N/A
(Former name or former address, if changed since last report.)
|
| |
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13a-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value |
AIKI |
The
Nasdaq Capital Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
On
August 9, 2022, the board of directors (the “Board”) of AIkido
Pharma Inc. (the “Company”) received an unsolicited proposal from
Shalom Auerbach to acquire all of the outstanding shares of the
Company for $8.00 per share in cash.
The Board reviewed and considered Mr. Auerbach’s proposal, and on
August 18, 2022, the Company’s counsel delivered a letter to Mr.
Auerbach informing him that the Board determined that it was not
interested in pursuing the offer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Dated: |
August 19, 2022 |
AIKIDO PHARMA INC. |
| |
|
|
|
| |
|
By: |
/s/ Anthony
Hayes |
| |
|
Name: |
Anthony Hayes |
| |
|
Title: |
Chief Executive Officer |
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From May 2023 to Jun 2023
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Jun 2022 to Jun 2023
